Phase II study of ramucirumab plus erlotinib for treatment-naïve patients with EGFR-mutant non-squamous non-small cell lung cancer and pleural effusion (RELAY-Effusion).

Kaneda H, Tachihara M, Toi Y, Kuyama S, Ichihara E, Fujisaka Y, Azuma K, Kurata T, Kubo A, Tanaka H, Yamada T, Yokoyama T, Kato T, Yamamoto K, Katakami N, Kawai R, Yoshida H, Shintani A, Sawa K, Kawaguchi T

Open source

DOI: 10.1016/j.lungcan.2026.109432
Published: 2026 Jul
Container: Lung cancer (Amsterdam, Netherlands)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.lungcan.2026.109432,
  title = {Phase II study of ramucirumab plus erlotinib for treatment-naïve patients with EGFR-mutant non-squamous non-small cell lung cancer and pleural effusion (RELAY-Effusion).},
  author = {Kaneda H and Tachihara M and Toi Y and Kuyama S and Ichihara E and Fujisaka Y and Azuma K and Kurata T and Kubo A and Tanaka H and Yamada T and Yokoyama T and Kato T and Yamamoto K and Katakami N and Kawai R and Yoshida H and Shintani A and Sawa K and Kawaguchi T},
  year = {2026},
  journal = {Lung cancer (Amsterdam, Netherlands)},
  doi = {10.1016/j.lungcan.2026.109432},
  url = {https://doi.org/10.1016/j.lungcan.2026.109432}
}

RIS

TY  - JOUR
TI  - Phase II study of ramucirumab plus erlotinib for treatment-naïve patients with EGFR-mutant non-squamous non-small cell lung cancer and pleural effusion (RELAY-Effusion).
AU  - Kaneda H
AU  - Tachihara M
AU  - Toi Y
AU  - Kuyama S
AU  - Ichihara E
AU  - Fujisaka Y
AU  - Azuma K
AU  - Kurata T
AU  - Kubo A
AU  - Tanaka H
AU  - Yamada T
AU  - Yokoyama T
AU  - Kato T
AU  - Yamamoto K
AU  - Katakami N
AU  - Kawai R
AU  - Yoshida H
AU  - Shintani A
AU  - Sawa K
AU  - Kawaguchi T
PY  - 2026
JO  - Lung cancer (Amsterdam, Netherlands)
DO  - 10.1016/j.lungcan.2026.109432
UR  - https://doi.org/10.1016/j.lungcan.2026.109432
ER  -

APA

H, K., M, T., Y, T., S, K., E, I., Y, F., K, A., T, K., A, K., H, T., T, Y., T, Y., T, K., K, Y., N, K., R, K., H, Y., A, S., K, S., & T, K. (2026). Phase II study of ramucirumab plus erlotinib for treatment-naïve patients with EGFR-mutant non-squamous non-small cell lung cancer and pleural effusion (RELAY-Effusion).. Lung cancer (Amsterdam, Netherlands). https://doi.org/10.1016/j.lungcan.2026.109432

Source records

pubmed · retrieved 2026-09-27T13:39:31.638Z